IFP Advisors Inc Buys 4,928 Shares of AbbVie Inc. (NYSE:ABBV)

IFP Advisors Inc raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 43,249 shares of the company's stock after purchasing an additional 4,928 shares during the quarter. IFP Advisors Inc's holdings in AbbVie were worth $7,685,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. GGM Financials LLC boosted its stake in AbbVie by 0.7% during the third quarter. GGM Financials LLC now owns 6,895 shares of the company's stock worth $1,362,000 after buying an additional 50 shares in the last quarter. Dillon & Associates Inc. boosted its holdings in AbbVie by 0.8% during the third quarter. Dillon & Associates Inc. now owns 6,914 shares of the company's stock valued at $1,362,000 after purchasing an additional 52 shares in the last quarter. WFA Asset Management Corp boosted its holdings in AbbVie by 0.8% during the third quarter. WFA Asset Management Corp now owns 7,003 shares of the company's stock valued at $1,383,000 after purchasing an additional 55 shares in the last quarter. Physicians Financial Services Inc. boosted its stake in AbbVie by 0.5% in the 4th quarter. Physicians Financial Services Inc. now owns 12,150 shares of the company's stock valued at $2,159,000 after buying an additional 55 shares in the last quarter. Finally, Carr Financial Group Corp boosted its stake in AbbVie by 1.1% in the 3rd quarter. Carr Financial Group Corp now owns 5,274 shares of the company's stock valued at $1,041,000 after buying an additional 56 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Stock Performance

AbbVie stock opened at $202.03 on Monday. The company has a current ratio of 0.66, a quick ratio of 0.54 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a market cap of $356.65 billion, a PE ratio of 84.18, a PEG ratio of 1.61 and a beta of 0.58. The company's 50-day moving average is $181.25 and its two-hundred day moving average is $186.41.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter last year, the business earned $2.79 earnings per share. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 273.33%.

Wall Street Analyst Weigh In

Several analysts recently commented on ABBV shares. Wolfe Research assumed coverage on AbbVie in a research note on Friday, November 15th. They issued an "outperform" rating and a $205.00 price target on the stock. Piper Sandler boosted their target price on shares of AbbVie from $212.00 to $220.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Raymond James restated an "outperform" rating and issued a $220.00 price target (up from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Leerink Partners upgraded shares of AbbVie from a "market perform" rating to an "outperform" rating and set a $206.00 price target on the stock in a research report on Friday, November 22nd. Finally, Truist Financial boosted their price target on shares of AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $208.35.

Insider Buying and Selling at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.25% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.